Lv3
246 积分 2024-05-28 加入
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
1天前
待确认
Second primary malignancies in multiple myeloma: A review
1天前
已完结
T-cell neoplasias and secondary malignancies after CAR-T cell therapy: current knowledge, risk factors, and implications from CAR-T engineering strategies
1天前
已完结
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma
3个月前
已完结
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53
3个月前
已完结
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
3个月前
已完结
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
6个月前
已完结
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
6个月前
已关闭
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis
6个月前
已关闭
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
6个月前
已关闭
皖公网安备34019202002308
